Patents Examined by Gregory S. Emch
  • Patent number: 10301379
    Abstract: The disclosure relates to antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau. The disclosure also relates to diagnostic, prophylactic and therapeutic methods using anti-tau antibodies.
    Type: Grant
    Filed: June 26, 2015
    Date of Patent: May 28, 2019
    Assignee: JANSSEN VACCINES & PREVENTION B.V.
    Inventors: Jehangir Wadia, Gabriel Pascual, Robert Anthony Williamson, Katarina Radosevic, Jaap Goudsmit
  • Patent number: 10286042
    Abstract: The invention provides methods for identifying, assessing, preventing, and treating neurological disorders and diseases using Fndc5 and modulators of Fndc5 expression or activity.
    Type: Grant
    Filed: October 1, 2014
    Date of Patent: May 14, 2019
    Assignee: Dana-Farber Cancer Institute, Inc.
    Inventors: Bruce M. Spiegelman, Christiane D. Wrann
  • Patent number: 10251937
    Abstract: Compositions, pharmaceutical compositions and biodegradable pharmaceutical compositions containing at least one analog of spadin or at least one analog of a propeptides of spadin or mixtures thereof are described. Methods for treating depression using the analogs of spadin or analogs of propeptides of spadin or mixtures thereof, as well as methods for blocking TREK-1 channel activity are also disclosed.
    Type: Grant
    Filed: January 27, 2015
    Date of Patent: April 9, 2019
    Assignees: MEDINCELL, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
    Inventors: Georges Gaudriault, Catherine Heurteaux, Jean Mazella, Marc Borsotto, Hamid Moha Ou Maati, Julie Veyssiere
  • Patent number: 10232056
    Abstract: The problem is to provide a method that can quickly and efficiently evaluate the toxicity of human cerebrospinal fluid (CSF) with small amounts of human CSF. The problem is solved by a method comprising administering human CSF into the cerebral ventricle of a rodent such as a mouse, and evaluating the cognitive function of the rodent by using a behavioral pharmacological technique.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: March 19, 2019
    Assignee: KYOWA HAKKO KIRIN CO., LTD.
    Inventors: Shinichi Uchida, Tomoyuki Kanda
  • Patent number: 10222368
    Abstract: An assay for Alzheimer's disease (AD) pathology in a living patient is disclosed wherein an amount of ?7nAChR or TLR4 in a FLNA-captured protein complex or ?7nAChR in an A?-captured protein complex or ?7nAChR-FLNA, TLR4-FLNA and/or ?7nAChR-A?42 complex present as a protein-protein complex in a sample is compared to the amount in a standard sample from a person free of AD pathology. An amount greater than in the standard sample indicates AD pathology. Also disclosed is an assay predictive of prognosis for treatment with a medicament in which the amount of an above protein or protein complex is compared to an amount in the presence of a medicament that binds to a FLNA pentapeptide and contains at least four pharmacophores of FIGS. 7-12. An amount of protein or protein complex determined in the presence of the medicament that is less than the first amount indicates a favorable treatment prognosis.
    Type: Grant
    Filed: May 27, 2016
    Date of Patent: March 5, 2019
    Assignee: Pain Therapeutics, Inc.
    Inventors: Hoau-Yan Wang, Lindsay Burns Barbier
  • Patent number: 10221220
    Abstract: The present invention relates to the provision of a biologically safe hemolymph sera, preferably hemocyanin, more preferably KLH (keyhole limpet hemocyanin). A method for producing virus free hemocyanin is provided.
    Type: Grant
    Filed: June 12, 2014
    Date of Patent: March 5, 2019
    Assignee: biosyn Arzneimittel GmbH
    Inventors: Ortwin Kottwitz, Thomas Stiefel, Shammana N. Muddukrishna
  • Patent number: 10208111
    Abstract: The invention describes antibodies having a high affinity for aggregated forms of ?-synuclein and a low affinity for monomeric forms of ?-synuclein. The antibodies are useful in the diagnosis of neurodegenerative diseases.
    Type: Grant
    Filed: November 18, 2016
    Date of Patent: February 19, 2019
    Assignee: United Arab Emirates University
    Inventor: Omar El-Agnaf
  • Patent number: 10208090
    Abstract: The invention relates to agents and to pharmaceutical compositions for reducing the formation of amyloid and/or for promoting the disaggregation of amyloid proteins. The compositions may also be used to detect amyloid.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: February 19, 2019
    Assignee: PROCLARA BIOSCIENCES, INC.
    Inventors: Rajaraman Krishnan, Richard Fisher
  • Patent number: 10203328
    Abstract: The present invention relates to mutated CSN5 polypeptides and their use in a method of screening modulators of CSN5 activity that could be used as therapeutic agents.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: February 12, 2019
    Assignee: University of Leicester
    Inventors: Aude Echalier, Christian Dumas, Melissa Birol
  • Patent number: 10197580
    Abstract: The invention relates to biomarkers and methods of diagnosing or monitoring schizophrenia, or a predisposition thereto.
    Type: Grant
    Filed: March 9, 2015
    Date of Patent: February 5, 2019
    Assignee: Cambridge Enterprises Limited
    Inventors: Sabine Bahn, Man Kuan Chan
  • Patent number: 10191068
    Abstract: The invention relates to antibodies, antibody fragments and binding agents that specifically recognize TDP-43 associated with frontotemporal dementia (FTD), but not TDP-43 associated with amyotrophic lateral sclerosis (ALS) or TDP-43 associated with healthy human brain tissue, and antibodies, antibody fragments and binding agents that specifically recognize TDP-43 associated with ALS, but not TDP-43 associated FTD or TDP-43 associated with healthy human brain tissue.
    Type: Grant
    Filed: February 2, 2015
    Date of Patent: January 29, 2019
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY
    Inventors: Michael Sierks, Stephanie Williams, Lalitha Venkataraman
  • Patent number: 10180423
    Abstract: Micropillar arrays for assaying differentiation of oligodendrocyte precursor cells into oligodendrocytes, ensheathment, and/or wrapping of the micropillars by the oligodendrocytes is provided. Also provided herein are methods of using the micropillar arrays for screening of candidate agents that promote differentiation of oligodendrocyte precursor cells into oligodendrocytes, ensheathment, and/or wrapping of the micropillars by the oligodendrocytes. A system comprising micropillar arrays and oligodendrocyte precursor cells are also provided.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: January 15, 2019
    Assignee: The Regents of the University of California
    Inventors: Jonah R. Chan, Seonok Lee
  • Patent number: 10167318
    Abstract: The present invention relates to novel D-enantiomeric A-beta-oligomer-binding peptides, homologs, fragments, parts and polymers thereof and use thereof.
    Type: Grant
    Filed: April 10, 2017
    Date of Patent: January 1, 2019
    Assignee: FORSCHUNGSZENTRUM JUELICH GMBH
    Inventors: Dieter Willbold, Susanne Aileen Funke, Oleksander Brener, Luitgard Nagel-Steger, Dirk Bartnik, Antonia Nicole Klein
  • Patent number: 10155808
    Abstract: A monoclonal antibody against human PrPc protein capable of reducing the expression level of transcription factor Twist1 in a targeting mode and inducing macrophage and NK cells to target to rectal cancer tumor cells. The combined drug therapy with the antibody and cetuximab also exhibits inhibitory effect on tumor better than administration of the antibody or cetuximab alone.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: December 18, 2018
    Assignee: Institute of Zoology, Chinese Academy of Sciences
    Inventors: Quan Chen, Baowei Li, Haiying Hang, Lei Du, Jun Wang, Xiaohui Wang
  • Patent number: 10144783
    Abstract: The invention provides diagnostic and therapeutic macromolecular compositions that cross the blood-brain barrier, in some embodiments in both directions, while allowing their activity to remain substantially intact once across the barrier. Also provided are methods for using such compositions in the diagnosis or treatment of CNS disorders such as Alzheimer's disease.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: December 4, 2018
    Assignee: ARMAGEN, INC.
    Inventors: William M. Pardridge, Ruben J. Boado
  • Patent number: 10138286
    Abstract: Methods and compositions are provided for reducing the effects of amyloid beta (A?) oligomers on a cell. Aspects of the methods generally include providing an agent that prevents A? oligomer activation of PirB/LILRB2 protein on cells, or providing a PirB/LILRB2 polypeptide composition to cells to prevent the A? oligomer activation of cells mediated by non-PirB/LILRB2 receptors. These methods find many uses, for example, in treating the decline in CNS function in individuals suffering from an A?-associated disease or disorder, and for screening candidate agents to identify new therapeutics that interfere with these toxic effects of A? in individuals having an A?-associated disease or disorder.
    Type: Grant
    Filed: March 10, 2014
    Date of Patent: November 27, 2018
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventors: Carla J. Shatz, Taeho Kim
  • Patent number: 10132818
    Abstract: The present invention relates to antibody-based probes (including single domain antibody fragment, scFv molecules, antibodies, antibody fragments, diabodies, and the epitope-binding domains thereof) that are capable of immunospecifically and selectively binding to a phospho-serine-containing epitope of Tau, such as, for example, Tau-phospho-serine 396/404 peptide. Such imaging ligands are useful to detect pathological Tau protein conformer if present in a biological sample, especially in conjunction with the diagnosis of Alzheimer's disease or other tauopathy, and thus provide a diagnostic for Alzheimer's disease and other Tau pathologies. The scFv molecules of the present invention have utility as diagnostic markers for, Alzheimer's disease and related tauopathies and as pharmaceutical compositions for the treatment of such conditions.
    Type: Grant
    Filed: July 6, 2015
    Date of Patent: November 20, 2018
    Assignee: New York University
    Inventor: Einar M. Sigurdsson
  • Patent number: 10131909
    Abstract: The present invention relates to a composition for improving memory including a Cyclin Y (CCNY) inhibitor as an active ingredient. More specifically, the present invention relates to a method for improving memory in a subject comprising administering the composition for improving memory to the subject. The present invention may reveal a CCNY-oriented molecular mechanism with respect to learning and memory, help understand causes of brain diseases associated with memory problems, and ultimately be applied in the treatment and diagnosis of brain memory disorders such as dementia.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: November 20, 2018
    Assignee: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY
    Inventors: Mikyoung Park, Eunsil Cho, Jung-Hwa Hong
  • Patent number: 10100362
    Abstract: Compositions and methods for the identification of agents useful for the treatment of neurological disorders, including schizophrenia, are provided.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: October 16, 2018
    Assignee: The Children's Hospital of Philadelphia
    Inventors: Hakon Hakonarson, Patrick Sleiman, Xiao Chang
  • Patent number: 10064921
    Abstract: Methods for preventing or treating neuropsychiatric disorder and/or a neurological disorder including a neurological disorder mediated by the thalamus. Neuropsychiatric disorders and/or a neurological disorders, including a thalamically mediated disorder can be treated by peripheral administration of a botulinum toxin to or to the vicinity of a trigeminal sensory nerve, thereby preventing or treating a neurological disorder and/or a neuropsychiatric disorder.
    Type: Grant
    Filed: March 2, 2017
    Date of Patent: September 4, 2018
    Assignee: Allergan, Inc.
    Inventor: Andrew M. Blumenfeld